PT3104838T - Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas - Google Patents

Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas

Info

Publication number
PT3104838T
PT3104838T PT157070194T PT15707019T PT3104838T PT 3104838 T PT3104838 T PT 3104838T PT 157070194 T PT157070194 T PT 157070194T PT 15707019 T PT15707019 T PT 15707019T PT 3104838 T PT3104838 T PT 3104838T
Authority
PT
Portugal
Prior art keywords
therapeutic
making
methods
same
nanoparticles
Prior art date
Application number
PT157070194T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT3104838T publication Critical patent/PT3104838T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT157070194T 2014-02-13 2015-02-13 Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas PT3104838T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461939363P 2014-02-13 2014-02-13

Publications (1)

Publication Number Publication Date
PT3104838T true PT3104838T (pt) 2020-02-14

Family

ID=52595474

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157070194T PT3104838T (pt) 2014-02-13 2015-02-13 Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas

Country Status (11)

Country Link
US (2) US10080723B2 (https=)
EP (1) EP3104838B1 (https=)
JP (1) JP6573895B2 (https=)
CA (1) CA2939261C (https=)
DK (1) DK3104838T3 (https=)
ES (1) ES2770733T3 (https=)
HU (1) HUE047934T2 (https=)
PL (1) PL3104838T3 (https=)
PT (1) PT3104838T (https=)
SI (1) SI3104838T1 (https=)
WO (1) WO2015123562A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3104838T1 (sl) 2014-02-13 2020-04-30 Pfizer Inc. Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev
JP6554493B2 (ja) 2014-06-24 2019-07-31 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティThe Trustees Of Princeton University 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス
HK1256704A1 (zh) 2015-08-21 2019-10-04 辉瑞公司 包含治疗剂的治疗性纳米粒及其制备和使用方法
EP3432864B1 (en) * 2016-03-22 2020-05-06 Pfizer Inc Process for preparing therapeutic nanoparticles
CA3060306A1 (en) 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US12357582B2 (en) 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
CN112236459A (zh) * 2018-04-23 2021-01-15 灰色视觉公司 改善的连续微粒制造
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
JP2025538488A (ja) * 2022-11-18 2025-11-28 ハイマ セラピューティクス,エルエルシー ペプチド修飾されたリポソーム用凍結乾燥緩衝液
TW202444365A (zh) 2023-01-31 2024-11-16 漢達生技醫藥股份有限公司 改良之卡博替尼組合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869884B2 (en) * 2002-08-22 2005-03-22 Chartered Semiconductor Manufacturing Ltd. Process to reduce substrate effects by forming channels under inductor devices and around analog blocks
WO2005009357A2 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
MX356097B (es) * 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
BR112015005878A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
ES2640648T3 (es) * 2013-09-16 2017-11-03 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
SI3104838T1 (sl) 2014-02-13 2020-04-30 Pfizer Inc. Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev
MA39734B1 (fr) * 2014-03-14 2019-07-31 Pfizer Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Also Published As

Publication number Publication date
US20190111004A1 (en) 2019-04-18
JP2017505800A (ja) 2017-02-23
US10583092B2 (en) 2020-03-10
US20170042828A1 (en) 2017-02-16
CA2939261A1 (en) 2015-08-20
WO2015123562A1 (en) 2015-08-20
HUE047934T2 (hu) 2020-05-28
DK3104838T3 (da) 2020-02-24
EP3104838B1 (en) 2020-01-01
EP3104838A1 (en) 2016-12-21
SI3104838T1 (sl) 2020-04-30
US10080723B2 (en) 2018-09-25
CA2939261C (en) 2023-03-28
ES2770733T3 (es) 2020-07-02
JP6573895B2 (ja) 2019-09-11
PL3104838T3 (pl) 2020-07-13

Similar Documents

Publication Publication Date Title
IL257318A (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
ZA201606646B (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IL250415B (en) Antibodies against pd-l and methods of using them
GB2554283B (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
SG11201703298SA (en) Activated bifidobacteria and methods of use thereof
PT3104838T (pt) Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos de fazer e utilizar as mesmas
GB201502084D0 (en) Catheter devices and related methods
SG10201406612RA (en) Mask structures and methods of manufacturing
GB201418350D0 (en) Dispenser and methods of use thereof
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
GB201404470D0 (en) Therapeutic methods and materials
IL249894A0 (en) Targeted medical nanoparticles and methods for their preparation and use
IL253234A0 (en) Methods for transdifferentiation and methods to use them
IL259047A (en) Nanoparticles containing a therapeutic substance, a process for their preparation and uses
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
ZA201606450B (en) Compounds and their methods of use
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
GB201418809D0 (en) Therapeutic agents and uses thereof
IL252508A0 (en) Oxidized lipids and their uses
GB2588276B (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
GB201417248D0 (en) Compostion and methods of treatment
GB201408171D0 (en) Formulation and method of manufacture
GB201403697D0 (en) Compounds and methods of use